Abstract: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inheritable kidney disorder, with a prevalence of one in 1000 individuals ([1][1]). Approximately 50% of patients with ADPKD progress to ESKD by the age of 60. Prior to the approval of tolvaptan, management of ADPKD was limited